Back to articles
Comparative guide · 7 min read

Curcumin vs Boswellia — anti-inflammatory botanicals compared

Updated 2026-05-12 · Reviewed by SupplementScore editors · No sponsorships

Curcumin and boswellia are the two most-studied botanical anti-inflammatories in the OTC supplement aisle, both with multiple positive RCTs in knee osteoarthritis at meaningful effect sizes. They differ in mechanism, absorption profile, side-effect concerns, and what other conditions the evidence extends to. The trial data is strong enough that both fit into a credible evidence-based joint-pain stack — and in head-to-head trials, the combination of curcumin + boswellia outperforms either alone. The question is rarely "pick one" but "pick what dominates a stack."

Quick verdict

GoalBetter choiceWhy
Knee osteoarthritis pain (head-to-head with NSAIDs) Both — similar effect size Multiple RCTs show non-inferiority to ibuprofen/diclofenac at 8–12 weeks for both botanicals.
Combined for OA pain Combination > either alone Curcumin + Boswellia (CB) combinations outperform single-agent in some head-to-head trials.
Inflammatory bowel disease maintenance (UC) Curcumin Curcumin has better trial evidence for ulcerative colitis remission maintenance.
Asthma adjunct Boswellia (modest signal) 5-LOX inhibition mechanism gives boswellia preliminary asthma evidence.
Speed of effect Boswellia (modestly) AKBA-standardised boswellia shows symptom changes within 1–4 weeks; curcumin trials typically need 4–8 weeks.
Side-effect profile Both well-tolerated Curcumin has rare hepatic signals at high doses with certain formulations; boswellia has GI signals.

How they work — different pathways

Curcumin — broad-spectrum NF-κB modulation

Curcumin, the principal curcuminoid in turmeric, modulates multiple inflammatory pathways — most prominently NF-κB activation, which sits upstream of multiple cytokine, chemokine, and prostaglandin pathways. The broad-spectrum mechanism explains why curcumin has trial evidence across many inflammatory conditions (OA, UC, depression adjunct, diabetic complications) at small to moderate effect sizes. The persistent problem is absorption — native curcumin has very low bioavailability and is rapidly conjugated and excreted; the trial evidence base is built on bioavailability-enhanced formulations (Meriva phytosome, Theracurmin, BCM-95, curcumin + piperine combinations).

Boswellia — selective 5-LOX inhibition

Boswellia (specifically the AKBA — acetyl-11-keto-β-boswellic acid — component) inhibits 5-lipoxygenase (5-LOX), an enzyme that produces leukotrienes from arachidonic acid. Leukotrienes are pro-inflammatory mediators particularly relevant in airway inflammation (asthma) and joint synovitis. The mechanism is narrower than curcumin's and produces a more specific signal in trial data — strong on OA, modest on asthma, less broadly applicable than curcumin. AKBA standardisation matters: many boswellia products list "65% boswellic acids" but contain very low AKBA, which is the more active 5-LOX inhibitor.

Trial evidence — OA is the strongest signal for both

For knee OA: Daily Daily 2016 meta-analysis (8 RCTs) found turmeric/curcumin extracts produced WOMAC pain reductions comparable to NSAIDs. The Apsara 2014 trial of CB (Curcuma longa + Boswellia serrata) combination vs celecoxib in knee OA found the herbal combination non-inferior on the WOMAC and global assessment scales. The Sengupta 2008 boswellia trial (5-LOXIN, AKBA-enriched) showed dose-dependent improvements in OA pain with onset of effect at 7 days. Across the combined evidence, both can be characterised as "non-inferior to standard NSAIDs at 8–12 weeks for knee OA, with substantially better GI safety."

Beyond OA — where the evidence diverges

Curcumin extends to: ulcerative colitis remission maintenance (Hanai 2006 trial showed improved remission rates at 6 months), depression adjunct (Lopresti meta-analyses), and small signals in diabetic nephropathy and lipid management. Boswellia extends to: asthma adjunct (small but consistent signal at AKBA-standardised doses), Crohn's disease (more limited evidence), and brain glioma adjunct (preliminary, off-label use). For non-joint indications, curcumin has the broader applicability.

Bioavailability — curcumin's defining problem

Native curcumin powder has bioavailability around 1% — most of an oral dose is conjugated, excreted in urine, or never absorbed. The trial data is built on enhanced formulations: Meriva (curcumin-phosphatidylcholine phytosome) ~20× absorption vs unformulated, Theracurmin ~30× via nano-particle technology, BCM-95 with turmerones, Curcumin C3 + Bioperine (95% curcuminoids + piperine 10 mg) modestly enhanced. Generic "turmeric extract" capsules at low cost will not deliver trial-level curcumin to plasma. This matters: if you're paying $5/month for a turmeric capsule, you're not getting the dose the trials studied. Boswellia bioavailability is less of an issue — AKBA-standardised extracts deliver measurable plasma levels at typical doses.

Practical rule. Both work for knee OA. The combination outperforms either alone in several head-to-head trials. If picking one: curcumin (in a bioavailability-enhanced formulation) for broader applicability beyond OA. Boswellia for OA-specific use, faster onset, and good asthma/airway adjunct evidence. The single most common mistake: buying unformulated turmeric capsules at low cost and expecting trial-level outcomes.

Dose, form, and timing

Curcumin: 1–2 g of curcuminoids/day from a bioavailability-enhanced formulation. Meriva (phytosome) 1 g/day delivers approximately the same plasma curcumin as 8+ g/day of unformulated turmeric. Take with a fatty meal. Branded options: Meriva, Theracurmin, BCM-95, Curcumin C3 + Bioperine. Curcumin C3 alone is unformulated — pair with piperine 5–10 mg or a fatty meal.

Boswellia: 100–250 mg of AKBA-standardised boswellia (e.g., 5-LOXIN at 30% AKBA, ApresFlex at higher AKBA loading), 1–3× per day with meals. Generic "boswellia 500 mg" capsules at unspecified AKBA content typically deliver much less active component than the AKBA-standardised products.

Safety and what to skip

Curcumin: generally well-tolerated. Mild GI symptoms most common. Rare hepatic signals (case reports of drug-induced liver injury, particularly with some commercial formulations — likely related to adulterants and bioavailability enhancers in some cases). Caution with anticoagulants — theoretical antiplatelet effect at high doses. Discuss with prescriber on chronic medications metabolised by CYP3A4.

Boswellia: generally well-tolerated. Mild GI symptoms most common. Theoretical caution with anticoagulants. Avoid in pregnancy.

Skip: "raw turmeric powder" capsules without bioavailability enhancement — won't deliver trial-level doses. Generic "Boswellia 500 mg" without AKBA standardisation — variable active content. Multi-ingredient "joint formulas" that under-dose every active component.

What the price difference buys you

Bioavailability-enhanced curcumin runs $20–50/month. AKBA-standardised boswellia runs $15–35/month. Combination products (curcumin + boswellia) at meaningful doses of both run $30–60/month. Compared to chronic NSAID use for OA (with the associated GI, cardiovascular, and renal risks), the price is competitive for users seeking NSAID-sparing alternatives.

Who should pick each

Pick curcumin if: you have knee OA plus another inflammatory condition (UC, depression, metabolic risk), you accept the higher cost of a bioavailability-enhanced formulation, you want broader anti-inflammatory coverage in a single supplement.

Pick boswellia if: knee OA is your primary indication, you want a faster onset (1–4 weeks), you have an asthma history that might benefit from 5-LOX inhibition.

Pick the combination if: knee OA is your primary indication and you want maximum effect — multiple head-to-head trials show CB combinations outperform either alone.

What we'd actually buy

For knee OA: a curcumin + boswellia combination product at trial-dose levels (e.g., Meriva 1 g/day + AKBA-standardised boswellia 100–200 mg 2–3×/day). Or buy each separately to control dose. Either is a credible NSAID-sparing approach to discuss with the prescriber.

For broader inflammatory conditions beyond joint pain: bioavailability-enhanced curcumin (Meriva or Theracurmin) 1 g/day.

Sources

Read more: